Agreement - September 2, 2015
AstraZeneca in license agreement with Daiichi Sankyo
AstraZeneca’s global biologics research and development arm, MedImmune, has entered an agreement with Daiichi Sankyo. The agreement grants the company an exclusive license to develop and commercialise FluMist Quadrivalent in Japan. FluMist Quadrivalent is a live attenuated influenza vaccine which is administered as a nasal spray and contains four protective strains. Phase III safety and efficacy […]
Collaboration - August 24, 2015
AZ, Peregrine to collaborate
AstraZeneca today announced that it has entered into a clinical trial collaboration with Peregrine Pharmaceuticals. The companies will evaluate the safety and efficacy of Peregrine’s investigational phosphatidylserine (PS)-signalling pathway inhibitor, bavituximab, in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial will evaluate the safety and efficacy of bavituximab in […]
Collaboration - August 10, 2015
MedImmune in strategic collaboration with Inovio Pharmaceuticals
MedImmune, AstraZeneca’s global biologics research and development arm, has entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases. Under the agreement, MedImmune will acquire exclusive rights to Inovio’s INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. INO-3112, which […]
In a new job - August 1, 2015
AZ appoints new Executive Vice President
AstraZeneca has appointed Sean Bohen MD, PhD, as Executive Vice President of Global Medicines Development and Chief Medical Officer. He will join the company on 15 September. Dr. Bohen will be responsible for driving the progress of AstraZeneca’s portfolio of small molecules and biologics investigational medicines through late-stage development to regulatory approval. As Chief Medical […]
Clinical Trials - July 22, 2015
AZ Drug Tested on Alzheimer’s
An AstraZeneca drug with disappointing results against solid tumors has shown promise in the treatment of Alzheimer’s disease, according to a team at Yale University in the U.S. The drug, AZD0530, attacks one of the key steps in the development of Alzheimer’s–blocking the activation of the enzyme FYN, which interrupts the synaptic connections between brain […]
Drug Development Pharma - July 18, 2015
Lung Cancer Drug Slows Disease
Astra Zeneca’s experimental lung cancer pill delayed the progression of the disease by more than a year, the company said at the European Lung Cancer Congress 2015 in Geneva, Switzerland, recently. The data came from the firm’s Phase II study on approximately 300 patients, which showed a 54 percent overall response rate, surpassing the 9.6-month […]
